[Clinical characteristics and management of patients with ST segment elevation myocardial infarction in China: survey of 7510 cases].
OBJECTIVE
To analyze the clinical characteristics and management of the patients with ST segment elevation myocardial infarction (STEMI) in China.


METHODS
As part of the international multicentre CREATE Study, the clinical data of 7510 patients with STEMI presenting their symptoms within 12 hours of onset who were hospitalized in 274 centers throughout China from July 2001 through July 2004, aged 62.7, were collected to be analyzed.


RESULTS
99.3% of these patients had STEMI, and 0.7% had new left bundle-branch block. 11.5% of them underwent percutaneous coronary intervention (PCI), 52.5% underwent thrombolytic therapy, and 0.1% coronary artery bypass grafting. All types of reperfusion therapy were carried out to 62.4% of the patients during the hospitalization. The medication therapy used was similar to those in the previous Registry report. The composite of all-cause mortality, re-infarction, and stroke within the first 7 days was 10.3% and the all-cause mortality within 30 days was 11.1%.


CONCLUSIONS
The clinical characteristics and management of the STEMI patients in China have been described. The age of onset of STEMI is 62 years on average. The most common complication is hypertension, and diabetes mellitus is relatively rare. rt-PA was used rarely mainly because of the expensive price. A large proportion of patients in China receive reperfusion, which is worth recommendation. Active intervention should be carried out in the early stage after infarction.
Yang
Yan-min
YM
Cardiovascular Institute and Fuwai Heart Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China.
Zhu
Jun
J
Tan
Hui-qiong
HQ
Liang
Yan
Y
Zhang
Yan
Y
Li
Jian-dong
JD
Liu
Li-sheng
LS
D000328:Adult; D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D000925:Anticoagulants / Q000627:therapeutic use; D002681:China; D004562:Electrocardiography; D005260:Female; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension / Q000150:complications; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000503:physiopathology / Q000628:therapy; D015912:Thrombolytic Therapy; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use*
D000925:Anticoagulants; D006493:Heparin; D014568:Urokinase-Type Plasminogen Activator